Literature DB >> 19944755

25-Hydroxyvitamin D(3) is an agonistic vitamin D receptor ligand.

Yan-Ru Lou1, Ferdinand Molnár, Mikael Peräkylä, Shengjun Qiao, Allan V Kalueff, René St-Arnaud, Carsten Carlberg, Pentti Tuohimaa.   

Abstract

25-Hydroxyvitamin D(3) 1alpha-hydroxylase encoded by CYP27B1 converts 25-hydroxyvitamin D(3) into 1alpha,25-dihydroxyvitamin D(3), a vitamin D receptor ligand. 25-Hydroxyvitamin D(3) has been regarded as a prohormone. Using Cyp27b1 knockout cells and a 1alpha-hydroxylase-specific inhibitor we provide in four cellular systems, primary mouse kidney, skin, prostate cells and human MCF-7 breast cancer cells, evidence that 25-hydroxyvitamin D(3) has direct gene regulatory properties. The high expression of megalin, involved in 25-hydroxyvitamin D(3) internalisation, in Cyp27b1(-/-) cells explains their higher sensitivity to 25-hydroxyvitamin D(3). 25-Hydroxyvitamin D(3) action depends on the vitamin D receptor signalling supported by the unresponsiveness of the vitamin D receptor knockout cells. Molecular dynamics simulations show the identical binding mode for both 25-hydroxyvitamin D(3) and 1alpha,25-dihydroxyvitamin D(3) with the larger volume of the ligand-binding pocket for 25-hydroxyvitamin D(3). Furthermore, we demonstrate direct anti-proliferative effects of 25-hydroxyvitamin D(3) in human LNCaP prostate cancer cells. The synergistic effect of 25-hydroxyvitamin D(3) with 1alpha,25-dihydroxyvitamin D(3) in Cyp27b1(-/-) cells further demonstrates the agonistic action of 25-hydroxyvitamin D(3) and suggests that a synergism between 25-hydroxyvitamin D(3) and 1alpha,25-dihydroxyvitamin D(3) might be physiologically important. In conclusion, 25-hydroxyvitamin D(3) is an agonistic vitamin D receptor ligand with gene regulatory and anti-proliferative properties.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19944755     DOI: 10.1016/j.jsbmb.2009.11.011

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  46 in total

1.  Indications on the use of vitamin D and vitamin D metabolites in clinical phenotypes.

Authors:  M L Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2010-09

2.  VDR and CYP27B1 are expressed in C2C12 cells and regenerating skeletal muscle: potential role in suppression of myoblast proliferation.

Authors:  Ratchakrit Srikuea; Xiping Zhang; Ok-Kyong Park-Sarge; Karyn A Esser
Journal:  Am J Physiol Cell Physiol       Date:  2012-05-30       Impact factor: 4.249

3.  Critique of the U-shaped serum 25-hydroxyvitamin D level-disease response relation.

Authors:  William B Grant
Journal:  Dermatoendocrinol       Date:  2009-11

Review 4.  Novel metabolic biomarkers of cardiovascular disease.

Authors:  Majken K Jensen; Monica L Bertoia; Leah E Cahill; Isha Agarwal; Eric B Rimm; Kenneth J Mukamal
Journal:  Nat Rev Endocrinol       Date:  2014-09-02       Impact factor: 43.330

5.  Ocular Pharmacokinetics of 25-Hydroxyvitamin D3 After Weekly Supplementation in Rabbits Using Ultra Performance Liquid Chromatography-Tandem Mass Spectrometer.

Authors:  Archit Kumar; Mini P Singh; Tripti Rungta; Ajay Patial; Savita Verma Attri; Bikash Medhi; Radha Kanta Ratho
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-10       Impact factor: 2.441

Review 6.  The immunoregulatory function of vitamin D: implications in chronic kidney disease.

Authors:  Kevin A Sterling; Parham Eftekhari; Matthias Girndt; Paul L Kimmel; Dominic S Raj
Journal:  Nat Rev Nephrol       Date:  2012-05-22       Impact factor: 28.314

7.  Fibroblast Growth Factor 23 Regulation by Systemic and Local Osteoblast-Synthesized 1,25-Dihydroxyvitamin D.

Authors:  Loan Nguyen-Yamamoto; Andrew C Karaplis; Rene St-Arnaud; David Goltzman
Journal:  J Am Soc Nephrol       Date:  2016-08-17       Impact factor: 10.121

8.  20-Hydroxyvitamin D2 is a noncalcemic analog of vitamin D with potent antiproliferative and prodifferentiation activities in normal and malignant cells.

Authors:  Andrzej T Slominski; Tae-Kang Kim; Zorica Janjetovic; Robert C Tuckey; Radoslaw Bieniek; Junming Yue; Wei Li; Jianjun Chen; Minh N Nguyen; Edith K Y Tang; Duane Miller; Tai C Chen; Michael Holick
Journal:  Am J Physiol Cell Physiol       Date:  2010-12-15       Impact factor: 4.249

9.  The induction of C/EBPβ contributes to vitamin D inhibition of ADAM17 expression and parathyroid hyperplasia in kidney disease.

Authors:  Maria Vittoria Arcidiacono; Jing Yang; Elvira Fernandez; Adriana Dusso
Journal:  Nephrol Dial Transplant       Date:  2014-10-07       Impact factor: 5.992

10.  Nano-encapsulation of vitamin D3 active metabolites for application in chemotherapy: formulation study and in vitro evaluation.

Authors:  Eyad Almouazen; Sandrine Bourgeois; Lars Petter Jordheim; Hatem Fessi; Stephanie Briançon
Journal:  Pharm Res       Date:  2012-12-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.